PAT Plus Three-Batch Validation Suggested As Transition Approach By FDA
This article was originally published in The Tan Sheet
Executive Summary
Process analytical technologies (PAT) and conventional manufacturing validation methods could be implemented concurrently as a way to avoid product introduction delays during the transition to the new validation approach, FDA suggests